Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 19/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213707 | 0.92 | OPRD1 (0.69) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5214067 | 0.90 | OPRD1 (0.68) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5212634 | 0.89 | OPRD1 (0.72) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5213631 | 0.89 | OPRD1 (0.66) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5213291 | 0.88 | OPRD1 (0.76) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5211611 | 0.88 | OPRD1 (0.61) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5211653 | 0.88 | OPRD1 (0.61) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5217382 | 0.88 | OPRD1 (0.77) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5215976 | 0.87 | OPRD1 (0.72) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5213708 | 0.87 | OPRD1 (0.63) | OPRD1OPRM1OPRK1KCNH2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567496-B1 | PHENYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2007-04-11 | — | — | EP | claimed |
| US-20060014789-A1 | Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | US | claimed |
| EP-1567496-B1 | PHENYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2007-04-11 | — | — | EP | disclosed |
| EP-1567496-B1 | PHENYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2007-04-11 | — | — | EP | disclosed |
| US-20060014789-A1 | Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | US | disclosed |
| EP-1567496-A1 | PHENYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004041784-A1 | PHENYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014789-A1 | Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders | TRPV1, TRPA1, OPRM1 | OPRD1 9/4885OPRM1 3/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.